Opioid Use Disorder Drugs

Core Concepts

The mu-opioid receptor: one target, three strategies

Opioid receptors are G-protein-coupled receptors that normally bind the body's own endorphins and enkephalins. Mu-receptor activation produces analgesia, euphoria, cough suppression, constipation, and — most dangerously — respiratory depression. Three behaviors are possible:

• Full agonist — maximal response. Strong analgesia and euphoria; overdose risk rises with dose and concurrent CNS depressants.
• Partial agonist — high-affinity binding but only a submaximal response even at full occupancy. Beyond a point, more drug produces no more effect (the ceiling effect).
• Antagonist — binds and produces no response while blocking other opioids. No euphoria, no analgesia, no respiratory depression from the drug itself.

Methadone: the full-agonist strategy

Methadone is a long-acting full mu-agonist that prevents withdrawal and reduces craving; steady receptor occupancy breaks the cycle of highs and lows that drives compulsive use. For OUD it is typically dispensed through opioid treatment programs (OTPs) with observed dosing; regulations vary by jurisdiction. Because it is a full agonist, risks include respiratory depression (especially early in treatment or with other CNS depressants) and QT-interval prolongation, so monitoring of consciousness, respiratory rate, and ECG findings per protocol matters.

Buprenorphine: the partial-agonist strategy

Buprenorphine has high affinity but low intrinsic activity at the mu receptor. Two consequences follow:

• Ceiling effect on respiratory depression — higher doses produce little additional respiratory depression, giving a wider safety margin and enabling office-based prescribing in many countries (scope varies).
• It can displace other opioids — because it binds more tightly, giving it while a full agonist still occupies receptors can trigger precipitated withdrawal. Patients must be in early withdrawal before the first dose; timing is prescriber-directed using withdrawal assessment, never guessed.

Buprenorphine is often formulated with naloxone to deter diversion: if crushed and injected, the naloxone blocks opioid effects; taken as directed (e.g., sublingually), it is largely inactive.

Naltrexone: the antagonist strategy

Naltrexone is a long-acting mu-antagonist: opioids produce no euphoria, so using becomes pointless. It has no abuse potential and causes no withdrawal on its own. Trade-offs: the person must already be opioid-free (fully withdrawn), or naltrexone itself precipitates severe withdrawal; and because there is no agonist effect, adherence is a challenge.

Withdrawal management versus long-term treatment

Withdrawal management (detoxification) is the short, medically supervised process of getting a person through acute withdrawal, often with tapering or symptom-directed medications; it does not by itself change the disorder's course. Long-term treatment — agonist, partial-agonist, or antagonist maintenance plus counseling — is what reduces relapse and death.

Nursing considerations

• Assess before and during therapy: level of consciousness, respiratory rate and depth, pupil size, withdrawal signs (validated scales such as the Clinical Opiate Withdrawal Scale, per facility policy), pain, mental status.
• Differentiate oversedation from withdrawal: sedation/constricted pupils/slow respirations suggest opioid effect; agitation, tearing, rhinorrhea, yawning, cramping, dilated pupils suggest withdrawal.
• Teach harm reduction: anyone with OUD or taking opioids should know about naloxone (emergency reversal agent) and how to call for help in an overdose.
• Discuss relapse risk: after abstinence, tolerance drops; relapsing to an old dose risks fatal overdose.
• Document objectively, use person-first language; scope and protocols vary by jurisdiction and institution.

Safety note: This is an educational overview of drug classes and mechanisms. Doses, induction timing, and monitoring schedules are determined by prescribers and program protocols. Verify everything against current references, the facility formulary, and prescriber orders.

Common Confusions